Skip to content

Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection

Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04724681
Acronym
WARD COVID-19
Enrollment
97
Registered
2021-01-26
Start date
2020-11-03
Completion date
2022-12-31
Last updated
2023-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Deterioration

Brief summary

For patients admitted with COVID-19 infection, it is often difficult to predict if or when their clinical condition will deteriorate. However subtle changes in vital signs are usually present 8 to 24 hours before a life-threatening event such as respiratory failure leading to ICU admission, or unanticipated cardiac arrest. Such adverse trends in clinical observations can be missed, misinterpreted or not appreciated as urgent. New continuous and wearable 24/7 clinical vital parameter monitoring systems offer a unique possibility to identify clinical deterioration before patients condition progress beyond the point-of-no-return, where adverse events are inevitable. The primary aim of this study is to test the effect of continuous wireless vital signs monitoring with generation of real-time alerts through a purpose-built GUI, compared to standard EWS monitoring on the cumulative duration of any severely deviating vital signs

Interventions

DEVICEWARD CSS

Wireless devices monitor vital signs continuously and transmit real-time data to an app that notifies clinical personnel when relevant deviations in vital signs occur This group will be monitored with standard Early Warning Score as well

Sponsors

Rigshospitalet, Denmark
CollaboratorOTHER
University Hospital Bispebjerg and Frederiksberg
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

A prospective controlled cohort study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (≥18 years). * Inclusion possible within 72 hours of admission, OR within 48 hours of discharge from an ICU to a medical ward * At least one expected overnight stay. * Patient admitted with confirmed COVID-19 infection

Exclusion criteria

* Patient expected not to cooperate with study procedures. * Allergy to plaster or silicone. * Patients admitted for palliative care only (i.e. no active treatment). * Patients previously enrolled in the studies WARD-COPD (H-18026653) or WARD-Surgery (H-17033535). * Inability to give informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative duration of deviating vital signs, heart rate > 130 min-1up to 16 daysCumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Heart rate \> 130 min-1
Cumulative duration of deviating vital signs, ScO2up to 16 daysCumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Lowest ScO2 (mean for ≥ 5 mins) min-1
Cumulative duration of deviating vital signs: SpO2 < 85% min-1up to 16 daysCumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● SpO2 \< 85% min-1
Cumulative duration of deviating vital signs, respiratory rate ≤ 5 min-1up to 16 daysCumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Respiratory rate ≤ 5 min-1
Cumulative duration of deviating vital signs, respiratory rate > 24 min-1up to 16 daysCumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Respiratory rate \> 24 min-1
Cumulative duration of deviating vital signs, heart rate ≤ 30 min-1up to 16 daysCumulative duration in minutes of the following deviations in vital signs during the monitoring period: ● Heart rate ≤ 30 min-1

Secondary

MeasureTime frameDescription
Change in vital parametersup to 16 daysChange in vital parameters one hour following an alarm as defined below Desaturation • Change in SpO2 60 minutes after an alarm has been triggered. (SpO2 \< 85 % for more than 5 minutes, SpO2 \< 80 % for more than 1 minutes, SpO2 \< 88 % for more than 10 minutes ) Tachypnea • Change in RR 60 minutes after an alarm has been triggered. (RR \>24 bpm for more than 5 minutes) Bradypnea/apnea • Change in RR and HR 60 minutes after an alarm has been triggered (RR ≤5 bpm AND HR \>20 bpm for more than one minute) Hypoventilation • Change in RR and SpO2 60 minutes after an alarm has been triggered. (RR \<11 bpm AND SpO2 \<88% for more than 5 minutes ) Tachycardia • Change in HR 60 minutes after an alarm has been triggered. (HR \>130 for more than 30 minutes, HR \>111 for more than 60 minutes) Bradycardia • Change in HR 60 minutes after an alarm has been triggered. (HR \<30 bpm for more than 1 minutes, HR 30-40 bpm for more than 5 minutes)
The frequency of events with desaturation as defined below and the simultaneous values of ScO2up to 16 daysThe frequency of events with desaturation as defined below and the simultaneous values of ScO2 * SpO2 \<80% \>1 min * SpO2 \<85% \> 5 min * SpO2 \<88% \> 10 min * SpO2 \<92% \> 60 min
Events with ScO2 < 60% for ≥ 1 minup to 16 daysThe frequency of events with ScO2 \< 60% for ≥ 1 min and the simultaneous measured SpO2 values
Frequency of predefined microevents (deviating vital signs)up to 16 daysThe frequency of micro events (deviating vital signs), measured by continuous vital sign monitoring and as measured by EWS in the control group The microevents are defined as follows, and the the outcome are frequency of these * RR ≤5 bpm AND HR \>20 bpm * RR ≥24 bpm * RR \<11 bpm AND SpO2 \<88 % * SpO2 \<80% * SpO2 \<85% * SpO2 \<88% * SpO2 \<92% * HR \>130 bpm * HR ≥111 bpm * HR \<30 bpm * HR = 30-40 bpm * Atrialflutter

Other

MeasureTime frameDescription
Duration of vital sign deviationup to 16 daysDuration of each of the following vital sign deviations * SpO2 \< 85% * Respiratory rate ≤ 5 min-1 * Respiratory rate \> 24 min-1 * Heart rate \> 130 min-1 * Heart rate ≤ 30 min-1 * Lowest ScO2 (mean for ≥ 5 mins)
Cumulative duration of ScO2 <60 % during admissionup to 16 daysCumulative duration of ScO2 \< 60 % related to the total time of NIRS monitoring
ECG pattern after alarmup to 16 daysECG pattern one hour following an AFLI alarm. (analysed with paired statistics within the continuously monitored group). The ECG pattern one hour following an alarm can be classified as either normal sinusrythm or AFLI
Adverse clinical ooutcomes6 monthsAny adverse clinical outcomes as defined in the protocol
Response to an alarmup to 16 daysStaff response time to an alarm (stratified according to time of day)
Contact to the attending doctor on callup to 16 daysnumber of times that the attending doctor on call is contacted during admission
Contact to intensive care physician on callup to 16 daysnumber of times that the intensive care physician on call is contacted during admission
Activation of Emergency Response Teamup to 16 daysnumber of times that the Emergency Response Teams is activated during admission
Invasive ventilationup to 16 daysThe frequency of invasive ventilation during admission
ICU admissionsup to 16 daysThe frequency of ICU admissions during admission
Length of stayup to 16 daysLength of stay (LOS) in days

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026